Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a research report on Thursday, August 21st. Wall Street Zen downgraded Novartis from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. Morgan Stanley upgraded Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price objective on the stock in a research report on Friday, August 8th. Novartis stock opened at $124.10 on Friday. Novartis Company Profile(Get Free Report)Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.